To further improve the predictive performance of the model, we combined the risk score and clinical parameters to construct a nomogram to predict the incidence of BCR at 3, 4, and 5 years after therapy for prostate cancer, and the results showed that the C-index was 0.683, with a certain degree of accuracy, and risk scores were independently associated with BCR (Figure 4E); and the calibration curves suggested a good predictive accuracy (Figure 4F). The gene discussed is BCR; the disease is prostate carcinoma.